Private equity firm MBK Partners will acquire Japan's Alinamin Pharmaceutical for 2.9 trillion won (US$2.1 billion), industry sources said Wednesday. MBK Partners will buy the Japanese supplement maker from U.S. investment fund Blackstone in a stock purchase deal to be signed later in the day, according to the sources. Alinamin Pharmaceutical, originally named Takeda Consumer Healthcare, a subsidiary of Japan's Takeda Pharmaceutical Co., was acquired by Blackstone in 2021. It is well-known for over-the-counter medicines, including vitamins. MBK Partners' acquisition of Alinamin represents the Korean equity firm's strategy to strengthen its health care business. It has recently taken over South Korea's leading dental implant firm Osstem Implant and 3D dental scanner maker Medit Corp. Source: Yonhap News Agency